AR038426A1 - Composicion de liberacion colonica - Google Patents
Composicion de liberacion colonicaInfo
- Publication number
- AR038426A1 AR038426A1 ARP030100480A ARP030100480A AR038426A1 AR 038426 A1 AR038426 A1 AR 038426A1 AR P030100480 A ARP030100480 A AR P030100480A AR P030100480 A ARP030100480 A AR P030100480A AR 038426 A1 AR038426 A1 AR 038426A1
- Authority
- AR
- Argentina
- Prior art keywords
- amylose
- colonic
- liberation
- composition
- ethyl cellulose
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000000112 colonic effect Effects 0.000 title 1
- 229920000856 Amylose Polymers 0.000 abstract 4
- 239000001856 Ethyl cellulose Substances 0.000 abstract 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 abstract 2
- 229920001249 ethyl cellulose Polymers 0.000 abstract 2
- 235000019325 ethyl cellulose Nutrition 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- WVKSUFYQOHQCMM-YGZHYJPASA-N prednisolone sulfobenzoate Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)C1=CC=CC(S(O)(=O)=O)=C1 WVKSUFYQOHQCMM-YGZHYJPASA-N 0.000 abstract 2
- 229950004954 prednisolone sulfobenzoate Drugs 0.000 abstract 2
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 abstract 1
- 241000209140 Triticum Species 0.000 abstract 1
- 235000021307 Triticum Nutrition 0.000 abstract 1
- 240000008042 Zea mays Species 0.000 abstract 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 235000005822 corn Nutrition 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente se refiere a una formulación de liberación controlada (preferentemente retardada) mejorada para la administración de metasulfobenzoato sódico de prednisolona. La formulación comprende metasulfobenzoato sódico de prednisolona rodeado por un recubrimiento que comprende amilosa vítrea, etilcelulosa y sebacato dibutílico, en donde la relación de amilosa a etilcelulosa es de 1:3,5 a 1:4,5 y en donde la amilosa es amilosa de trigo ó maíz.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0203421.3A GB0203421D0 (en) | 2002-02-13 | 2002-02-13 | Composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038426A1 true AR038426A1 (es) | 2005-01-12 |
Family
ID=9931006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100480A AR038426A1 (es) | 2002-02-13 | 2003-02-13 | Composicion de liberacion colonica |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20050220861A1 (es) |
| EP (1) | EP1474116A1 (es) |
| JP (1) | JP2005521682A (es) |
| CN (1) | CN100350913C (es) |
| AR (1) | AR038426A1 (es) |
| AU (1) | AU2003212491B2 (es) |
| CA (1) | CA2475704C (es) |
| GB (1) | GB0203421D0 (es) |
| MX (1) | MXPA04007894A (es) |
| MY (1) | MY137423A (es) |
| RU (1) | RU2327446C2 (es) |
| TW (1) | TWI291354B (es) |
| WO (1) | WO2003068196A1 (es) |
| ZA (1) | ZA200406397B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0607534D0 (en) | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
| AU2007279036A1 (en) * | 2006-07-27 | 2008-01-31 | University Of Sunderland | Coating composition comprising starch |
| JP2010523555A (ja) | 2007-04-04 | 2010-07-15 | シグモイド・ファーマ・リミテッド | 「経口医薬組成物」 |
| ES2425762T3 (es) * | 2008-10-27 | 2013-10-17 | Roquette Freres | Polímero insoluble en agua: revestimientos de película a base de derivados de almidón modificado para la liberación dirigida al colon |
| EP2298321A1 (en) | 2009-08-26 | 2011-03-23 | Nordic Pharma | Novel pharmaceutical compositions for treating IBD |
| CA2885680C (en) | 2011-09-07 | 2022-10-04 | Roland Saur-Brosch | Formulation for the controlled release of one or several substances in the digestive tract of a mammal. |
| NO2659881T3 (es) | 2012-04-30 | 2018-04-28 | ||
| GB201304662D0 (en) | 2013-03-14 | 2013-05-01 | Sigmoid Pharma Ltd | Compositions |
| US10799515B2 (en) | 2013-10-29 | 2020-10-13 | Tillotts Pharma Ag | Delayed release drug formulation |
| EP3409688A1 (en) | 2017-05-31 | 2018-12-05 | Tillotts Pharma Ag | Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof |
| EP3459529A1 (en) | 2017-09-20 | 2019-03-27 | Tillotts Pharma Ag | Preparation of sustained release solid dosage forms comprising antibodies by spray drying |
| EP3459527B1 (en) | 2017-09-20 | 2022-11-23 | Tillotts Pharma Ag | Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization |
| ES2938609T3 (es) | 2017-09-20 | 2023-04-13 | Tillotts Pharma Ag | Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión |
| EP3662902B1 (en) | 2018-12-07 | 2024-07-31 | Tillotts Pharma AG | Colonic drug delivery formulation |
| WO2020114616A1 (en) | 2018-12-07 | 2020-06-11 | Tillotts Pharma Ag | Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof |
| EP3662901A1 (en) | 2018-12-07 | 2020-06-10 | Tillotts Pharma AG | Delayed release drug formulation comprising an outerlayer with an enzymaticyaaly degradable polymer, its composition and its method of manufacturing |
| EP3662898A1 (en) | 2018-12-07 | 2020-06-10 | Tillotts Pharma AG | Solid composition comprising mesalazine |
| EP3662900A1 (en) | 2018-12-07 | 2020-06-10 | Tillotts Pharma AG | Colonic drug delivery formulation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8926639D0 (en) * | 1989-11-24 | 1990-01-17 | Agricultural & Food Res | Delayed release formulations |
| DK0652701T3 (da) * | 1992-07-31 | 2002-04-29 | Goodman Fielder Ltd | Stivelse med høj amyloseindhold og resistente stivelsesfraktioner |
| GB9620709D0 (en) * | 1996-10-04 | 1996-11-20 | Danbiosyst Uk | Colonic delivery of weak acid drugs |
| GB9722426D0 (en) * | 1997-10-23 | 1997-12-24 | Univ London Pharmacy | Controlled release formulations |
| GB9724186D0 (en) * | 1997-11-14 | 1998-01-14 | British Tech Group | Low temperature coatings |
| US20010053791A1 (en) * | 2000-03-16 | 2001-12-20 | Babcock Walter C. | Glycogen phosphorylase inhibitor |
-
2002
- 2002-02-13 GB GBGB0203421.3A patent/GB0203421D0/en not_active Ceased
-
2003
- 2003-02-11 TW TW092102742A patent/TWI291354B/zh not_active IP Right Cessation
- 2003-02-13 US US10/504,182 patent/US20050220861A1/en not_active Abandoned
- 2003-02-13 AU AU2003212491A patent/AU2003212491B2/en not_active Ceased
- 2003-02-13 EP EP03708310A patent/EP1474116A1/en not_active Withdrawn
- 2003-02-13 MY MYPI20030494A patent/MY137423A/en unknown
- 2003-02-13 WO PCT/GB2003/000651 patent/WO2003068196A1/en active Application Filing
- 2003-02-13 JP JP2003567379A patent/JP2005521682A/ja active Pending
- 2003-02-13 AR ARP030100480A patent/AR038426A1/es unknown
- 2003-02-13 CN CNB038050137A patent/CN100350913C/zh not_active Expired - Fee Related
- 2003-02-13 MX MXPA04007894A patent/MXPA04007894A/es unknown
- 2003-02-13 RU RU2004127867/15A patent/RU2327446C2/ru not_active IP Right Cessation
- 2003-02-13 CA CA2475704A patent/CA2475704C/en not_active Expired - Fee Related
-
2004
- 2004-08-12 ZA ZA200406397A patent/ZA200406397B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003212491A1 (en) | 2003-09-04 |
| TWI291354B (en) | 2007-12-21 |
| CN1638746A (zh) | 2005-07-13 |
| ZA200406397B (en) | 2005-09-12 |
| CN100350913C (zh) | 2007-11-28 |
| RU2327446C2 (ru) | 2008-06-27 |
| WO2003068196A1 (en) | 2003-08-21 |
| MXPA04007894A (es) | 2004-10-15 |
| EP1474116A1 (en) | 2004-11-10 |
| AU2003212491B2 (en) | 2008-04-17 |
| MY137423A (en) | 2009-01-30 |
| CA2475704A1 (en) | 2003-08-21 |
| TW200302744A (en) | 2003-08-16 |
| RU2004127867A (ru) | 2005-06-10 |
| CA2475704C (en) | 2011-07-12 |
| US20050220861A1 (en) | 2005-10-06 |
| GB0203421D0 (en) | 2002-04-03 |
| JP2005521682A (ja) | 2005-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038426A1 (es) | Composicion de liberacion colonica | |
| NO20042596L (no) | Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1 | |
| MA30725B1 (fr) | Administration d'inhibiteurs de la dipeptidyl peptidase | |
| WO2007056073A3 (en) | Medical device with a coating comprising an active form and an inactive form of therapeutic agent(s) | |
| CO4700474A1 (es) | Formulacion oral de 2-metil-tieno-benzodiacepina | |
| NO20050771L (no) | Bicifadinformulering | |
| WO2005112635A3 (en) | Uridine effects on dopamine release | |
| GB2388778B (en) | Method and composition for combatting pesticide resistance | |
| SI1539114T1 (sl) | Filmska obloga za tablete in kaplete | |
| HRP20041013B1 (hr) | Formulacija visoke doze ibandronata | |
| NO20045385L (no) | Farmasoytisk preparat inneholdende okskarbazepin med kontrollert frigivelse av aktivt stoff | |
| RS44204A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| PL350419A1 (en) | Directly compressible matrix for controlled release of single daily doses of clarithromycin | |
| DK1392251T3 (da) | Fremgangsmåde til tabletindkapsling | |
| DE69930648D1 (de) | Orale darreichungsform für pyridin-2-ylmethylsulfinyl-1h-benzimidazole | |
| DK1847258T4 (da) | Partialglycerider som smøremiddel til farmaceutiske sammensætninger indeholdende thieno[3,2-c]pyridin-derivater | |
| BRPI9916820B8 (pt) | composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método | |
| RS44304A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| NO20071977L (no) | Stabilisert farmasoytisk formulering av leukotrien b4 (ltb4)-middel | |
| AU3903701A (en) | Diclofenac pharmaceutical composition based on vitamin-e, papain and hyaluronidase | |
| EA200500613A1 (ru) | Фармацевтические композиции с контролируемым высвобождением, содержащие альгинат натрия и альгинат натрия-кальция | |
| AU2001292423A1 (en) | Formulations for reducing or eliminating toxicity of environmental hormones containing ursodeoxycholic acid | |
| WO2004045611A8 (en) | Use of a thiazolidinedione for the reduction of side effects of chemotherapy | |
| BRPI0415716A (pt) | derivados do ácido acremÈnico | |
| MY137801A (en) | Tablet for oral administration comprising 2-[(4-methoxy-3-methyl)-2-pyridinyl]methylsulfinyl-5-(1h-pyrrol-1-yl)-1h-benzimidazole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |